Drug Type Contrast agent, Small molecule drug  | 
Synonyms PMI 03, PMI03  | 
Target-  | 
Action enhancers  | 
Mechanism Magnetic resonance imaging enhancers  | 
Active Indication  | 
Inactive Indication-  | 
Originator Organization  | 
Active Organization  | 
Inactive Organization-  | 
License Organization-  | 
Drug Highest PhasePhase 1  | 
First Approval Date-  | 
Regulation-  | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Alzheimer Disease | Phase 1 | South Korea   | 30 Jan 2022 | |
| Neuroinflammation | Phase 1 | South Korea   | 30 Jan 2022 | |
| Parkinson Disease | Phase 1 | South Korea   | 30 Jan 2022 | |
| Neurodegenerative Diseases | Phase 1 | United States   | 22 Aug 2019 | |
| Inflammation | Phase 1 | United States   | 28 Jul 2019 | |
| Nerve Degeneration | Phase 1 | - | - | 





